Every 10-Q that Illumina Inc (ILMN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ILMN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ILMN filings page.
Illumina, Inc. reported Q3 2025 results with total revenue of $1,084 million, essentially flat year over year ($1,080 million). Product revenue was $927 million, led by sequencing consumables at $747 million, while service and other revenue was $157 million. Net income was $150 million, or $0.98 diluted EPS. Income from operations was $227 million, reflecting higher gross margin versus last year’s mix and the absence of prior-year settlement credits.
Year to date, revenue was $3,184 million and net income reached $516 million. Cash from operations was $758 million, supporting $706 million of share repurchases (7.45 million shares) under a $1.5 billion authorization. Cash and cash equivalents were $1,050 million, short‑term investments $228 million, and term debt totaled $1,992 million (with $998 million current). The company disclosed $747 million in remaining performance obligations (77% expected within 12 months) and noted ongoing headwinds in Greater China. Illumina agreed to acquire SomaLogic and certain assets from Standard BioTools for $350 million in cash, plus up to $75 million in milestones, subject to regulatory approvals, with expected closing in the first half of 2026.